



Bayer Yakuhin, Ltd.
Santen Pharmaceutical Co., Ltd.

Bayer Yakuhin and Santen Pharmaceuticals extend co-promotion agreement for Eylea[®] (aflibercept intravitreal injection) in Japan

Bayer Yakuhin, Ltd. (Head office : Osaka, hereafter referred to as “Bayer Yakuhin”) and Santen Pharmaceutical Co., Ltd. (Head office : Osaka, hereafter referred to as “Santen”) announced the signing of an agreement to extend the co-promotion of Eylea[®] (aflibercept intravitreal injection) in Japan.

Both companies have been jointly promoting the intravitreal VEGF* inhibitor Eylea[®] (aflibercept intravitreal injection) in Japan under a co-promotion agreement concluded in May 2012. Under the extended agreement, Santen continues to be responsible for distributing Eylea[®] in Japan, while Bayer Yakuhin continues to hold the marketing authorization for the product. Both companies will jointly conduct detailing activities at medical institutions and provide information about the product to medical professionals.

* VEGF=vascular endothelial growth factor

“We are pleased to extend our collaboration with Santen to support doctors in bringing the benefits of Eylea[®] to Japanese patients. Building on our seven years of successful partnership, we will continue to work closely with Santen to deliver the latest scientific information about Eylea[®] to the Japanese ophthalmology community and contribute to improvement in treatment outcomes for its approved indications,” said Heike Prinz, President of Bayer Yakuhin.

“Based on the existing agreement, Santen has worked together with Bayer Yakuhin to address unmet needs for retinal diseases, particularly age-related macular degeneration, which is still one of the top causes of blindness in Japan. We will continue to contribute to improving the quality of life of patients by delivering innovative treatments like Eylea[®] to patients,” said Takeshi Ito, Director, Executive Corporate Officer, Head of Japan Business, and Head of Japan Sales and Marketing Division of Santen.

For the year ended March 31, 2019, Santen's Eylea sales was 56.157 billion yen. Santen has no plans to revise their full-year financial forecasts as a result of this agreement.

About EYLEA® (aflibercept solution for injection)

Eylea® is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Eylea® acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PGF) and thereby can inhibit the binding and activation of their cognate VEGF receptors.

Eylea® has been approved in Japan for indications to treat patients with: age-related macular degeneration with subfoveal choroidal neovascularization (wet AMD), macular edema due to retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV) and diabetic macular edema (DME). In July this year, Bayer filed an application for approval as a treatment for neovascular glaucoma (NVG).

Bayer and Regeneron Pharmaceuticals Inc. are collaborating on the global development of Eylea®. Regeneron maintains exclusive rights to Eylea® in the United States. Bayer has licensed the exclusive marketing rights outside the United States.

Contact:

Bayer Japan Pharmaceuticals
Communications Tel: +81-6-6133-7333

Santen Pharmaceutical Co., Ltd.
Corporate Communications Group
Tel: +81-6-4802-9360

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.

About Bayer Yakuhin, Ltd.

Bayer Yakuhin, Ltd., headquartered in Osaka, is a healthcare company which combines business activities of Pharmaceuticals, Consumer Health and Animal Health (companion and farm animal products). Pharmaceuticals business is focused on the following areas: Cardiovascular & Neurology, Oncology & Hematology, Women's Healthcare, Ophthalmology and Radiology. Bayer Yakuhin aims to be one of leading pharmaceutical companies, which responds to Japanese patients' unmet medical needs. More information is available at www.byl.bayer.co.jp/

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

About Regeneron Pharmaceuticals

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Forward-Looking Statements of Bayer

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Forward-Looking Statements of Santen

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.